Table 1. Baseline characteristics in cases and all matched controls by database (QResearch or CPRD).
| |
QResearch |
CPRD |
||
|---|---|---|---|---|
| Cases | Controls | Cases | Controls | |
| Total |
91 556 |
427 674 |
88 845 |
415 383 |
| Breast | 24 489 | 113 945 | 25 444 | 118 835 |
| Prostate | 26 554 | 124 230 | 23 176 | 108 102 |
| Lung | 17 961 | 83 992 | 19 059 | 89 471 |
| Bladder | 7464 | 34 786 | 7084 | 32 984 |
| Skin | 4998 | 23 399 | 4621 | 21 654 |
| Ovary | 3427 | 16 089 | 3088 | 14 532 |
| Pancreas | 3593 | 16 818 | 3485 | 16 200 |
| Uterus | 2248 | 10 570 | 2149 | 10 125 |
| Cervix |
822 |
3845 |
739 |
3480 |
|
Sex | ||||
| Male | 47 193 (51.5) | 220 492 (51.6) | 43 596 (49.1) | 203 487 (49.0) |
| Female |
44 363 (48.5) |
207 182 (48.4) |
45 249 (50.9) |
211 896 (51.0) |
|
Age band (years) | ||||
| 30–54 | 7345 (8.0) | 34 000 (7.9) | 6998 (7.9) | 32 749 (7.9) |
| 55–64 | 22 786 (24.9) | 106 266 (24.8) | 22 071 (24.8) | 104 095 (25.1) |
| 65–74 | 30 410 (33.2) | 143 528 (33.6) | 28 407 (32.0) | 134 902 (32.5) |
| 75–84 | 26 177 (28.6) | 122 798 (28.7) | 23 864 (26.9) | 112 533 (27.1) |
| 85+ |
4838 (5.3) |
21 082 (4.9) |
7505 (8.4) |
31 104 (7.5) |
| Ethnicity |
|
|
|
|
| White | 21 477 (23.5) | 90 874 (21.2) | 7034 (7.9) | 30 294 (7.3) |
| Not recordeda | 69 131 (75.5) | 331 241 (77.5) | 78 841 (88.7) | 371 491 (89.4) |
| Non-white | 948 (1.0) | 5559 (1.3) | 2970 (3.3) | 13 598 (3.3) |
| Asianb | 364 (0.4) | 2726 (0.6) | 194 (0.2) | 1516 (0.4) |
| Blackb | 397 (0.4) | 1834 (0.4) | 166 (0.2) | 649 (0.2) |
| Otherb |
187 (0.2) |
999 (0.2) |
2610 (2.9) |
11 433 (2.8) |
|
Deprivation, Townsend quintile | ||||
| 1, most affluentc | 23 442 (26.3) | 110 919 (26.7) | 9753 (30.5) | 45 736 (30.6) |
| 2c | 19 959 (22.4) | 94 167 (22.7) | 7695 (24.0) | 36 203 (24.2) |
| 3c | 18 032 (20.2) | 84 427 (20.3) | 6253 (19.5) | 29 740 (19.9) |
| 4c | 15 768 (17.7) | 72 202 (17.4) | 5007 (15.6) | 23 075 (15.4) |
| 5, most deprivedc | 12 075 (13.5) | 53 799 (12.9) | 3290 (10.3) | 14 914 (10.0) |
| Not recorded |
2280 (2.5) |
12 160 (2.8) |
56 847 (64.0) |
265 715 (64.0) |
|
BMI (kg m−2) | ||||
| 15–24c | 27 225 (38.0) | 120 028 (37.3) | 29 310 (39.1) | 131 726 (38.3) |
| 25–29c | 28 956 (40.4) | 130 874 (40.7) | 29 808 (39.7) | 138 713 (40.3) |
| 30–49c | 15 409 (21.5) | 70 904 (22.0) | 15 913 (21.2) | 73 554 (21.4) |
| Not recorded |
19 966 (21.8) |
105 868 (24.8) |
13 814 (15.5) |
71 390 (17.2) |
|
Smoking status | ||||
| Non-smokerc | 34 949 (41.4) | 182 349 (48.0) | 40 128 (47.6) | 21 2180 (55.4) |
| Ex-smokerc | 31 475 (37.3) | 136 575 (36.0) | 26 958 (32.0) | 112 142 (29.3) |
| Current light smokerc | 5633 (6.7) | 20 787 (5.5) | 3966 (4.7) | 13 871 (3.6) |
| Current moderate smokerc | 7825 (9.3) | 26 747 (7.0) | 8838 (10.5) | 30 846 (8.1) |
| Current heavy smokerc | 4467 (5.3) | 13 187 (3.5) | 4382 (5.2) | 13 646 (3.6) |
| Not recorded |
7207 (7.9) |
48 029 (11.2) |
4573 (5.1) |
32 698 (7.9) |
|
Use of alcohol | ||||
| No usec | 22 061 (29.9) | 101 997 (30.5) | 19 714 (25.8) | 92 647 (26.6) |
| Ex usec | 2030 (2.7) | 7672 (2.2) | ||
| Lightc | 44 809 (60.7) | 203 342 (60.8) | 44 448 (58.1) | 204 556 (58.8) |
| Moderate and morec | 7009 (9.5) | 29 036 (8.7) | 10 250 (13.4) | 42 911 (12.3) |
| Not recorded |
17 677 (19.3) |
93 299 (21.8) |
12 403 (14.0) |
67 597 (16.3) |
|
Comorbidities | ||||
| Upper GI | 19 250 (21.0) | 83 377 (19.5) | 24 302 (27.4) | 107 660 (25.9) |
| Diabetes | 8140 (8.9) | 36 769 (8.6) | 7990 (9.0) | 37 011 (8.9) |
| Pancreatitis | 492 (0.5) | 1981 (0.5) | 552 (0.6) | 2102 (0.5) |
| Hypertension | 31 466 (34.4) | 142 577 (33.3) | 31 169 (35.1) | 142 474 (34.3) |
| Chronic kidney disease | 3444 (3.8) | 15 558 (3.6) | 3710 (4.2) | 16 425 (4.0) |
| Rheumatoid arthritis | 1424 (1.6) | 6591 (1.5) | 1673 (1.9) | 7310 (1.8) |
| Benign breast disease |
2727 (3.0) |
10 077 (2.4) |
2761 (3.1) |
9653 (2.3) |
|
History of osteoporosis | ||||
| Osteoporosis/osteopenia | 3682 (4.0) | 16 998 (4.0) | 4023 (4.5) | 18 474 (4.4) |
| Osteoporotic fractures |
3322 (3.6) |
16 013 (3.7) |
2375 (2.7) |
10 342 (2.5) |
| Family history of cancer |
2841 (3.1) |
11 756 (2.7) |
2836 (3.2) |
11 364 (2.7) |
|
Medications (excluding past 6 months) | ||||
| Acid-lowering drugs | 32 523 (35.5) | 14 0637 (32.9) | 33 531 (37.7) | 145 409 (35.0) |
| NSAIDs | 52 422 (57.3) | 233 143 (54.5) | 55 106 (62.0) | 248 518 (59.8) |
| Corticosteroids | 14 156 (15.5) | 57 106 (13.4) | 13 908 (15.7) | 54 233 (13.1) |
| Calcium | 1023 (1.1) | 4816 (1.1) | 6286 (7.1) | 28 984 (7.0) |
| Vitamin D | 4891 (5.3) | 22 582 (5.3) | 4960 (5.6) | 23 035 (5.5) |
| Hormone replacementd | 12 071 (13.2) | 51 861 (12.1) | 12 633 (14.2) | 55 666 (13.4) |
| Oral contraceptivesd |
773 (0.8) |
3551 (0.8) |
1236 (1.4) |
5490 (1.3) |
|
Bisphosphonates | ||||
| Any | 3827 (4.2) | 17 883 (4.2) | 3769 (4.2) | 17 490 (4.2) |
| Alendronate | 2589 (2.8) | 12 010 (2.8) | 2538 (2.9) | 11 969 (2.9) |
| Etidronate | 1286 (1.4) | 5949 (1.4) | 1170 (1.3) | 5471 (1.3) |
| Risedronate | 851 (0.9) | 3985 (0.9) | 806 (0.9) | 3715 (0.9) |
| Ibandronate |
74 (0.1) |
435 (0.1) |
75 (0.1) |
353 (0.1) |
|
Other osteoporosis drugs | ||||
| Any | 319 (0.3) | 1641 (0.4) | 333 (0.4) | 1685 (0.4) |
| Raloxifen | 192 (0.2) | 1032 (0.2) | 217 (0.2) | 1081 (0.3) |
| Strontium | 95 (0.1) | 456 (0.1) | 97 (0.1) | 509 (0.1) |
| Calcitonin | 38 (0.0) | 207 (0.0) | 34 (0.0) | 162 (0.0) |
Abbreviations: CPRD=Clinical Practice Research Datalink; GI=gastrointestinal; NSAID=non-steroidal anti-inflammatory drugs.
Values are numbers and %.
a
Assumed White for the analyses.
b
Broken down categories for non-White group.
c
Proportion only within recorded data.
d
Only for women cancers.